TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21079154

Group type: EXPERIMENTAL
Intervention: BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Consolidation therapy for rapid responders (females: 4 cycles of COPP/ABV without IFRT; males: 2 cycles of ABVD with IFRT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: BEACOPP chemotherapy with IFRT for slow responders
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Secondary leukemias
Number of subjects: 99
Study: 21079158

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control (age-matched, no oncological treatment)
Number of subjects: 141
Study: 21079979

Group type: EXPERIMENTAL
Intervention: Seasonal variation and environmental influence (climatic changes and environmental pollution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence of spina bifida
Number of subjects: 0
Study: 21080009

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system
Number of subjects: 54
Study: 21083386

Group type: EXPERIMENTAL
Intervention: Kidney transplantation in HIV-infected patients
Number of subjects: 150
Study: 21083543

Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment (80 mg at week 0 and 40 mg eow starting at week 1)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment
Number of subjects: 285
Study: 21083592

Group type: EXPERIMENTAL
Intervention: Silymarin use
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Control (non-users of silymarin)
Number of subjects: 1049
Study: 21083644

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21084397

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 74
Study: 21085552

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) consisting of 6 weekly sessions and 3 telephone booster calls.
Number of subjects: 23
Study: 21086246

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® 120 mg at 56-day interval
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® 120 mg at 42-day interval
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® 120 mg at 28-day interval
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lanreotide Autogel® 120 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 35
Study: 21086905

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 21087331

Group type: EXPERIMENTAL
Intervention: Appropriate ICD shocks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Inappropriate ICD shocks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nonsustained ventricular tachycardia
Number of subjects: 134
Study: 21087756

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Metallic platform stents (MPS)
Number of subjects: 191
Study: 21087953

Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF) treatment delivered by an encapsulated cell technology implant in one eye
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham surgery in the contralateral eye
Number of subjects: 3
Study: 21087958

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg)
Number of subjects: 62
Study: 21088439

Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 57
Study: 21091740

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No RER (control group)
Number of subjects: 69
Study: 21092279

Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy applied to sputum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (normal sputum)
Number of subjects: 50
Study: 21093024

Group type: EXPERIMENTAL
Intervention: AMG 317 (IL-4 receptor α antagonist)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Individual components of the ACQ
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Composite ACQ score measurement
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 21093448

Group type: EXPERIMENTAL
Intervention: ANRS HIV-LIPO-5 Vaccine (dendritic cell vaccine loaded with HIV-1-antigen lipopeptides)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANRS HIV-LIPO-5 Vaccine
Number of subjects: 0
Study: 21093611

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor
Number of subjects: 271
Study: 21093871

Group type: EXPERIMENTAL
Intervention: SAI QRST (sum magnitude of the absolute QRST integral)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: SAI QRST not exceeding 145 mV ms
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: High SAI QRST
Number of subjects: 508
Study: 21094089

Group type: EXPERIMENTAL
Intervention: Navitoclax (14/21 dosing schedule) at doses of 10, 20, 40, 80, 110, 160, 225, 315, or 440 mg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Navitoclax (21/21 dosing schedule) at doses of 200, 275, 325, or 425 mg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Navitoclax (150 mg/day lead-in dose followed by 325 mg on continuous 21/21 schedule)
Number of subjects: 55
Study: 21095016

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNPs (rs4938016, rs2734848, rs2734841, rs1124493, rs1076562)
Number of subjects: 0
Study: 21095488

Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV) 20 to 80 mg/kg/d for up to 48 weeks
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV)
Number of subjects: 152
Study: 21098399

Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice daily)
Number of subjects: 321
Study: 21098436

Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus drug-eluting vascular scaffold
Number of subjects: 45
Study: 21098526

Group type: EXPERIMENTAL
Intervention: Pre-PCV7
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Early post-PCV7
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Late post-PCV7
Number of subjects: 3
Study: 21098574

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 20
Study: 21106443

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 631

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 631
Study: 21106711

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ERα polymorphisms
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ERα PvuII T>C polymorphism
Number of subjects: 115
Study: 21106722

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ipilimumab with multipeptide immunizations (HLA-A*0201+ patients)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher changes in Th-17 inducible frequency
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher baseline C-reactive protein (CRP) levels
Number of subjects: 75
Study: 21107682

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day plus vinorelbine and trastuzumab
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Everolimus 30 mg/week plus vinorelbine and trastuzumab
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Everolimus 20 mg/week plus vinorelbine and trastuzumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 21108818

Group type: EXPERIMENTAL
Intervention: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A (3.75 μg haemagglutinin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A
Number of subjects: 100
Study: 21109011

Group type: EXPERIMENTAL
Intervention: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support; Induction with anthracyclin-containing regimen followed by tandem HDT conditioned by high-dose mitoxantrone plus cytarabine for the first HDT and total-body irradiation (TBI), carmustine, etoposide, and cyclophosphamide for the second HDT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support
Number of subjects: 45
Study: 21109229

Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK) with low-dose mitomycin C (MMC) 0.002% for 1 minute
Number of subjects: 23
Study: 21109344

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study: 21109690

Group type: EXPERIMENTAL
Intervention: Karyotyping
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 302
Study: 21110749

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 0
Study: 21110865

Group type: EXPERIMENTAL
Intervention: French speaking areas
Number of subjects: 542

Group type: COMPARATOR
Intervention: Swiss parents
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Maternal workload and parental education
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Regional differences
Number of subjects: 542
Study: 21111785

Group type: EXPERIMENTAL
Intervention: High dose (5.0mg, n=12)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low dose (1.0mg, n=10)
Number of subjects: 22
Study: 21111983

Group type: EXPERIMENTAL
Intervention: Practice-based performance improvement intervention
Number of subjects: 15170
Study: 21115606

Group type: EXPERIMENTAL
Intervention: Patients' perception of COPD symptoms
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Breathlessness as a symptom
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Daily and/or weekly symptom variability
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Factors associated with perception of variability
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Perception of variability by region
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Impact on daily activities
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Adjustment of treatment
Number of subjects: 2441
Study: 21117946

Group type: COMPARATOR
Intervention: Candesartan 32 mg + Hydrochlorothiazide 25 mg (Phase 1)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg + Hydrochlorothiazide 25 mg (Phase 2)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg + Hydrochlorothiazide 25 mg + Amlodipine 5 mg (optional extension)
Number of subjects: 186
Study: 21118562

Group type: EXPERIMENTAL
Intervention: Paleolithic diet (n = 14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Mediterranean-like diet (n = 15)
Number of subjects: 29
Study: 21118739

Group type: EXPERIMENTAL
Intervention: New disposable rhGH injection pen
Number of subjects: 136
Study: 21123095

Group type: EXPERIMENTAL
Intervention: Self-completed WIQ (Walking Impairment Questionnaire)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Supervision of self-completed WIQs
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall WIQ score
Number of subjects: 73
Study: 21123449

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for obstructive sleep apnea (OSA) for 8 weeks
Number of subjects: 0
Study: 21123592

Group type: EXPERIMENTAL
Intervention: Palm technology for data collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21123825

Group type: EXPERIMENTAL
Intervention: L-asparaginase-based treatment
Number of subjects: 19
Study: 21124227

Group type: EXPERIMENTAL
Intervention: HAART-exposed infants
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Zidovudine-exposed infants
Number of subjects: 1059
Study: 21126328

Group type: EXPERIMENTAL
Intervention: HRP2-based rapid diagnostic test (Paracheck)
Number of subjects: 300

Group type: COMPARATOR
Intervention: HC microscopy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Expert microscopy
Number of subjects: 300
Study: 21127362

Group type: EXPERIMENTAL
Intervention: Vascular syringes (RPD syringe)
Number of subjects: 437
Study: 21129762

Group type: EXPERIMENTAL
Intervention: Ambisome plus miltefosine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Ambisome
Number of subjects: 135

Group type: COMPARATOR
Intervention: miltefosine
Number of subjects: 135
Study: 21130380

Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 21131369

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 800 mg/day (continuous)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 400 mg b.i.d.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 800 mg/day (intermittent)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 180-800 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses ≤1000 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at maximum tolerated dose (MTD) of 800 mg/day
Number of subjects: 90
Study: 21131410

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21131552

Group type: EXPERIMENTAL
Intervention: ENMD-2076 at 200 mg/m(2)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ENMD-2076 at 160 mg/m(2) (MTD)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ENMD-2076 (various doses: 60, 80, 120, 160, 200 mg/m(2))
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ENMD-2076 (specifically in patients with platinum refractory/resistant ovarian cancer)
Number of subjects: 67
Study: 21131590

Group type: EXPERIMENTAL
Intervention: IgG from patients with acquired hemophilia
Number of subjects: 65
Study: 21134243

Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin once between days 1-3 and once between days 5-8 post-transplant
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin
Number of subjects: 13
Study: 21134574

Group type: EXPERIMENTAL
Intervention: HIV-positive children
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: LTNPs
Number of subjects: 364
Study: 21134978

Group type: EXPERIMENTAL
Intervention: NRAS mutations in patients with advanced disease
Number of subjects: 44

Group type: COMPARATOR
Intervention: NRAS mutations in patients with indolent systemic mastocytosis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clonal mast cells with mutations
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: KIT-D816V detection in bone marrow CD34(+) progenitors
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NRAS mutation presence in bone marrow CD34(+) progenitors
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Impact of NRAS and KIT mutations on mast cell survival
Number of subjects: 44
Study: 21134985

Group type: EXPERIMENTAL
Intervention: PR1 and WT1 peptides in Montanide-adjuvant with GM-CSF, administered every two weeks for a total of 6 injections
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Booster injection three months after the 6th vaccine dose
Number of subjects: 8
Study: 21135146

Group type: EXPERIMENTAL
Intervention: EGFR TKI with T790M mutation
Number of subjects: 93

Group type: COMPARATOR
Intervention: EGFR TKI without T790M mutation
Number of subjects: 93
Study: 21135251

Group type: EXPERIMENTAL
Intervention: Mitomycin C treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized xenograft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global genomic sequencing
Number of subjects: 0
Study: 21138567

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 15
Study: 21138605

Group type: EXPERIMENTAL
Intervention: Wheat bran (9 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fibre control
Number of subjects: 10
Study: 21138939

Group type: EXPERIMENTAL
Intervention: sFlt-1 >84 ng/L
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: PlGF >20 ng/L
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Combination of troponin T and sFlt-1
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: sFlt-1 and PlGF together with hsTnT
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: sFlt-1
Number of subjects: 763

Group type: COMPARATOR
Intervention: hsTnT
Number of subjects: 763
Study: 21139079

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scans
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Clinical symptoms or blood counts
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: CT scan results
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: CT scan or ultrasound results
Number of subjects: 1372
Study: 21139575

Group type: EXPERIMENTAL
Intervention: Low-dose peginterferon α2a
Number of subjects: 831

Group type: COMPARATOR
Intervention: No antiviral therapy
Number of subjects: 831
Study: 21140148

Group type: EXPERIMENTAL
Intervention: Imatinib (dosing modified to achieve target plasma levels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard imatinib dosing
Number of subjects: 0
Study: 21142268

Group type: EXPERIMENTAL
Intervention: Exenatide ER 0.8 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Exenatide ER 2 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 21143432

Group type: EXPERIMENTAL
Intervention: Extended release methylphenidate (OROS MPH) at a mean dose of 54 mg/day (0.90 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy comparators (control group)
Number of subjects: 0
Study: 21144043

Group type: EXPERIMENTAL
Intervention: Xenform® Matrix (bovine dermal graft)
Number of subjects: 45
Study: 21144055

Group type: EXPERIMENTAL
Intervention: HOP'N after-school program
Number of subjects: 715
Study: 21145590

Group type: EXPERIMENTAL
Intervention: Daunorubicin combined with imatinib mesylate (600 mg/d) and cytarabine (200 mg/d for 7 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daunorubicin at 30-45 mg/m(2)/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of IM with a standard '3+7' regimen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (SCT)
Number of subjects: 36
Study: 21145720

Group type: EXPERIMENTAL
Intervention: 24 μg formoterol
Number of subjects: 37
Study: 21145855

Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a (180μg/week)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a with ribavirin
Number of subjects: 163

Group type: COMPARATOR
Intervention: PEG-IFN therapy (0-4 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: PEG-IFN therapy (5-19 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: PEG-IFN therapy (20-23 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: PEG-IFN therapy (24 weeks)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: ≥80/80 PEG-IFN adherence
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Missed doses during therapy
Number of subjects: 163
Study: 21146669

Group type: EXPERIMENTAL
Intervention: Left ventricular systolic dysfunction (LVSD)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Clinical heart failure (HF)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Overall prevalence of LVSD/HF
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Electrocardiographic conduction abnormalities
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Interval ≥240 milliseconds
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: QRS duration ≥120 milliseconds
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Presence of LVSD/HF
Number of subjects: 406
Study: 21147030

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with an endometrial thickness cutoff of 5.15 mm
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 5 mm or greater
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 5 mm or greater plus endometrial abnormalities
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 10 mm or greater
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 5 mm in women with no symptoms of postmenopausal bleeding
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening in a high-risk population with a cutoff of 6.75 mm
Number of subjects: 48230
Study: 21148082

Group type: EXPERIMENTAL
Intervention: CD56(+) APL patients treated with all-trans retinoic acid and anthracycline-based regimens
Number of subjects: 651

Group type: COMPARATOR
Intervention: CD56(-) APL patients treated with all-trans retinoic acid and anthracycline-based regimens
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: CD56(+) APL patients
Number of subjects: 651
Study: 21148334

Group type: EXPERIMENTAL
Intervention: Surgical resection followed by chemotherapy
Number of subjects: 345

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 345
Study: 21148530

Group type: EXPERIMENTAL
Intervention: Adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Number of subjects: 135
Study: 21148532

Group type: EXPERIMENTAL
Intervention: Monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1)
Number of subjects: 131
Study: 21148541

Group type: EXPERIMENTAL
Intervention: Medtronic Engager™ aortic valve bioprosthesis (23 mm size)
Number of subjects: 30
Study: 21148613

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally days 1-28, every 42 days (1 cycle)
Number of subjects: 77